Stocks & Investing
Stocks and Investing
Stocks and Investing
Mon, January 28, 2019
[ Mon, Jan 28th 2019
] - WOPRAI
[ Mon, Jan 28th 2019
] - WOPRAI
Fri, January 25, 2019
[ Fri, Jan 25th 2019
] - WOPRAI
[ Fri, Jan 25th 2019
] - WOPRAI
[ Fri, Jan 25th 2019
] - WOPRAI
[ Fri, Jan 25th 2019
] - WOPRAI
[ Fri, Jan 25th 2019
] - WOPRAI
Thu, January 24, 2019
[ Thu, Jan 24th 2019
] - WOPRAI
[ Thu, Jan 24th 2019
] - WOPRAI
[ Thu, Jan 24th 2019
] - WOPRAI
[ Thu, Jan 24th 2019
] - WOPRAI
[ Thu, Jan 24th 2019
] - WOPRAI
[ Thu, Jan 24th 2019
] - WOPRAI
[ Thu, Jan 24th 2019
] - WOPRAI
Wed, January 23, 2019
[ Wed, Jan 23rd 2019
] - WOPRAI
[ Wed, Jan 23rd 2019
] - WOPRAI
[ Wed, Jan 23rd 2019
] - WOPRAI
[ Wed, Jan 23rd 2019
] - WOPRAI
[ Wed, Jan 23rd 2019
] - WOPRAI
[ Wed, Jan 23rd 2019
] - WOPRAI
[ Wed, Jan 23rd 2019
] - WOPRAI
[ Wed, Jan 23rd 2019
] - WOPRAI
[ Wed, Jan 23rd 2019
] - WOPRAI
[ Wed, Jan 23rd 2019
] - WOPRAI
[ Wed, Jan 23rd 2019
] - WOPRAI
David Amsellem Upgraded (TEVA) to Hold and Increased Target to $16 on, Jan 23rd, 2019
David Amsellem of Piper Sandler, Upgraded "Teva Pharmaceutical Industries Limited" (TEVA) to Hold and Increased Target from $15 to $16 on, Jan 23rd, 2019.
David has made no other calls on TEVA in the last 4 months.
There are 4 other peers that have a rating on TEVA. Out of the 4 peers that are also analyzing TEVA, 1 agrees with David's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Ami Fadia of "Leerink Swann" Upgraded from Sell to Hold on, Monday, October 1st, 2018
These are the ratings of the 3 analyists that currently disagree with David
- Jason Gerberry of "B of A Securities" Upgraded from Sell to Strong Buy on, Thursday, January 3rd, 2019
- David Risinger of "Morgan Stanley" Upgraded from Hold to Buy and Held Target at $27 on, Monday, November 5th, 2018
- Jami Rubin of "Goldman Sachs" Maintained at Strong Buy and Held Target at $30 on, Monday, October 1st, 2018
